Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies.
In this study, we have utilized the human high molecular weight-melanoma associated antigen (HMW-MAA) as a target for active specific immunotherapy with mouse anti-idiotypic (anti-id) monoclonal antibodies (mAb) in patients with malignant melanoma. After having summarized the characteristics of HMW-MAA which account for its selection as a target for immunotherapy, we describe the development and characterization of mouse anti-id mAb MK2-23 which bears the internal image of HMW-MAA. Furthermore, we describe the results of the first clinical trial performed with mouse anti-id mAb MK2-23 in patients with malignant melanoma.
Ferrone
S
S
Department of Microbiology and Immunology, New York Medical College, Valhalla 10595.
Kageshita
T
T
Hirai
S
S
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active; D008545:Melanoma / Q000401:mortality / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D051379:Mice; D008807:Mice, Inbred BALB C; D009363:Neoplasm Proteins / Q000276:immunology*; D012878:Skin Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins